Metabolomic Profiling of Disease Progression Following Radiotherapy for Breast Cancer.

ABSTRACT:

Background

This study aims to explore metabolic biomarkers and pathways in breast cancer prognosis.

Methods

We performed a global post-radiotherapy (RT) urinary metabolomic analysis of 120 breast cancer patients: 60 progression-free (PF) patients as the reference and 60 with progressive disease (PD: recurrence, second primary, metastasis, or death). UPLC-MS/MS (Metabolon Inc.) identified 1742 biochemicals (1258 known and 484 unknown structures). Following normalization to osmolality, log transformation, and imputation of missing values, a Welch's two-sample t-test was used to identify biochemicals and metabolic pathways that differed between PF and PD groups. Data analysis and visualization were performed with MetaboAnalyst.

Results

Metabolic biomarkers and pat

SUBMITTER: McMahon AN 

PROVIDER: S-EPMC11899340 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature